Referências

1. Leys, D., Atherothrombosis: a major health burden (2011) Cerebrovasc. Dis, 11 SUPPL. 2, pp. 1-4
2. Quist-Paulsen, P., Naess, I.A., Canniegieter, S.C., Romundstad, P.R., Christiansen, S.C., Rosendaal, F.R., Hammerstrom, J., Arterial cardiovascular risk factors and venous thrombosis: results from a population-based prospective study (the HUNT 2) (2010) Haematologica, 95, pp. 119-125
3. Linden, M.D., Jackson, D.E., Platelets: pleiotropic roles in atherogenesis and Atherothrombosis (2011) Int. J. Biochem. Cell. Biol, 42, pp. 1762-1766
4. Koenen, R.R., Weber, C., Platelet derived chemokines in vascular remodeling and atherosclerosis Semin. Thromb. Hemost, 2010, pp. 163-169
5. Aukrust, A.P., Halvorsen, B., Ueland, T., Michelson, A.E., Skjelland, M., Gullestad, L., Yndestad, A., Otterdal, K., Activated platelets and atherosclerosis (2010) Expert Rev. Cardiovasc. Ther, 8, pp. 1297-1307
6. Drouet, L., Baldit Solllier, C., Henry, P., (2010) Drugs, 70 SUPPL. 1, pp. 9-14
7. Coccheri, S., Antiplatelet drugs-do we need new options? With a reappraisal of direct thromboxane inhibitors (2010) Drugs, 70, pp. 887-908
8. Buch, M.H., Prendergast, B.D., Storey, R.F., Anti-platelet therapy and vascular disease: an update (2010) Ther. Adv. Cardiovasc. Dis, 4, pp. 249-275
9. Kenet, G., Lutkhoff, L.K., Albisetti, M., Bernard, T., Bonduel, M., Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies (2010) Circulation, 121, pp. 1837-1847
10. Muszbek, L., Bereczky, Z., Bagoly, Z., Shemirani, A.H., Katona, E., Factor XIII and atherothrombotic diseases (2010) Semin. Thromb. Hemost, 36, pp. 18-33
11. Mousa, S., Antithrombotic effects of naturally derived products on coagulation and platelet function (2010) Anticoagulants, antiplatelets and thrombolytics, 663, pp. 229-240. , Edited by Mousa, S. Methods in Molecular Biology
12. Bernard, T.J., Manco-Johnson, M.J., Goldenberg, N.A., The role of anatomic factors, thrombophilia and antithrombin therapies in childhood onset arterial ischemic stroke (2010) Thromb. Res, 127, pp. 6-12
13. Venter, J.C., Adams, M.D., Myers, E.W., Peter, W., Mural, R.J., The sequence of human genome (2001) Science, 291, pp. 1304-1135
14. Mälarstig, A., Hamsten, A., Genetics of atherothrombosis and thrombophilia (2010) Curr. Atheroscler. Rep, 12, pp. 159-166
15. Hansson, G.K., Inflammation, atherosclerosis and coronary artery disease (2005) N Engl. J. Med, 352, pp. 1685-1695
16. Martinelli, I., Bucciarelli, P., Mannucci, P.M., Thrombotic risk factors: basic pathophysiology (2010) Crit. Care Med, 38 SUPPL, pp. S3-S9
17. Esmon, C.T., Basic mechanisms and pathogenesis of venous thrombosis (2009) Blood Rev, 23, pp. 225-229
18. Van de Poll, T., de Boer, J.D., Levi, M., The effect of inflammation on coagulation and vice-versa (2011) Curr. Opin. Infect. Dis, 24, pp. 273-278
19. Levi, M., van der Poll, T., Inflammation and coagulation (2010) Crit. Care Med, 38 SUPPL. 2, pp. S26-S34
20. Naess, I.A., Christiansen, S.C., Romundstad, P., Cannegieter, S.C., Rosendaal, F.R., Hammerstrom, J., Incidence and mortality of venous thrombosis: a population-based study (2007) J. Thromb. Haemost, 5, pp. 692-699
21. Rosendaal, F.R., Reitsma, P.H., Genetics of venous thrombosis (2009) J. Thromb. Haemost, 7 SUPPL. 1, pp. 301-304
22. Lane, D.A., Mannucci, P.M., Bauer, K.A., Bertina, R.M., Bochkov, N.P., Boulyjenko, V., Chandy, M., Dahlbäck, B., Inherited thrombophilia (1996) Part I. Thrmob. Haemost, 76, pp. 651-662
23. Soare, A.M., Popa, C., Deficiencies of proteins C, S and antithrombin and factor V Leiden and the risk of ischemic strokes (2010) J. Med. Life, 3, pp. 235-238
24. Bertina, R.M., Molecular risk factors for thrombosis (1999) Thromb. Haemost, 82, pp. 601-609
25. Spector, E.B., Grody, W.W., Matteson, C.J., Palomaki, G.E., Bellissimo, D.B., Wolff, D.J., Bradley, L.A., Richards, C.S., Technical Standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210GA testing): A disease-specific supplement to the Standards and guidelines for clinical genetics laboratories (2005) Genet. Med, 7, pp. 444-453
26. Ridker, P.M., Miletich, J.P., Hennekens, C.H., Buring, J.E., Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening JAMA, 277, pp. 1305-1307
27. Emmerich, J., Rosendaal, F.R., Cattaneo, M., Margaglione, M., de Stefano, V., Cumming, T., Arruda, V., Reny, J.L., Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls (2001) Thromb. Haemost, 86, pp. 809-813
28. Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Bertina, R.M., A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis (1996) Blood, 88, pp. 3698-3703
29. Bozic-Mijovski, M., Hyperhomocysteinemia and thrombophilia (2010) Clin. Chem. Lab. Med, 48 SUPPL, pp. 589-595
30. Den Heijer, M., Rosendaal, F.R., Blom, H.J., Gerrits, W.B., Bos, G.M., Hyperhomocysteinemia and venous thrombosis: a meta-analysis (1998) Thromb. Haemost, 80, pp. 874-877
31. Den Heijer, M., Brouwer, I.A., Bos, G.M., Blom, H.J., van der Put, N.M., Spaans, A.P., Rosendaal, F.R., Gerrits, W.B., Vitamin supplementation reduces blood homocysteine levels (1998) Arterioscler. Thromb. Vasc. Biol, 18, pp. 356-361
32. Den Heijer, M., Willems, H.P., Blom, H.J., Gerrits, W.B., Cattaneo, M., Eichinger, S., Rosendaal, F.R., Bos, G.M., Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, Double-blind Trial (2007) Blood, 109, pp. 139-144
33. Rees, M.M., Rodgers, G.M., Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis (1993) Thromb. Res, 71, pp. 337-359
34. Kang, S.-S., Zhou, J., Wong, P.W., Kowalisyn, J., Strokosch, G., Intermediate homocysteinemia: a thermo-labile variant of methylene-tetra-hydrofolate reductase (1988) Am. J. Hum. Genet, 43, pp. 414-421
35. Selhub, J., Jacques, P.F., Wilson, P.W., Rush, D., Rosenberg, I.H., Vitamin status and intake as primary determinants of homocysteinemia in an elderly population (1993) J. Am. Med. Assoc, 270, pp. 2693-2698
36. Cooper, P.C., Coath, F., Daly, M.E., Makris, M., The phenotypic and genetic assessment of antithrombin deficiency (2011) Int. J. Lab. Hem, 33, pp. 227-237
37. Patnaik, M.M., Moll, S., Inherited antithrombin deficiency: a review (2008) Haemophilia, 14, pp. 1229-1239
38. Ishiguro, K., Kojima, T., Kadomatsu, K., Nakayama, Y., Takagi, A., Suzuki, M., Takeda, N., Saito, H., Complete antithrombin deficiency in mice results in embryonic lethality (2000) J. Clin. Invest, 106, pp. 873-878
39. Castoldi, E., Rosing, J., APC resistance: biological basis and acquired influences (2009) J. Thromb. Haemost, 8, pp. 445-453
40. Segers, O., Castoldi, E., Factor V Leiden and activated protein C resistance (2009) Adv. Clin. Chem, 49, pp. 121-157
41. Griffin, J.H., Fernandez, J.Á., Gale, A.J., Mosnier, L.O., Activated protein C (2007) J. Thromb. Haemost, 5 SUPPL. 1, pp. 73-80
42. Navarro, S., Bonet, E., Estellés, A., Montes, R., Hermida, J., Martos, L., España, F., Medina, P., The endothelial cell protein C receptor: its role in thrombosis (2011) Thromb. Res, 128, pp. 410-416
43. Dahlbäck, B., Villoutreiv, B.O., The anticoagulant protein C pathway (2005) FEBS Lett, 579, pp. 3310-3316
44. Norstrom, E.A., Steen, M., Tran, S., Dahlbäck, B., Importance of proteins and phospholipid for activated protein C-mediated cleavages in factor Va (2003) J. Biol. Chem, 278, pp. 24904-24911
45. Dawson, S., Wiman, B., Hamstem, A., Green, F., Humphries, S., Henney, A.M., The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells (1993) J. Biol. Chem, 268, pp. 10739-10745
46. Lane, D.A., Grant, P.J., Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease (2000) Blood, 95, pp. 1517-1532
47. Smith, E.B., Haemostatic risk factors for cardiovascular diseases (1998) Eur. Heart J, 19, pp. 39-43
48. Tsantes, A.E., Nikolopoulos, G.K., Bagos, P.G., Bonovas, S., Kopterides, P., Vaiopoulos, G., The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk (2008) Thromb. Res, 122, pp. 736-742
49. Tanis, B.C., Rosendaal, F.R., Venous and arterial thrombosis during oral contraceptive use: risk and risk factors (2003) Semi. Vasc. Med, 3, pp. 69-84
50. Rosendaal, F.R., Van Hylckama, V.A., Tanis, B.C., Helmerhorst, F.M., Estrogens, progestogens and thrombosis (2003) J. Thromb. Haemost, 1, pp. 1371-1380
51. Mohllajee, A.P., Curtis, K.M., Martins, S.L., Peterson, H.B., Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review (2005) Contraception, 73, pp. 166-178
52. Vaya, A., Mira, Y., Mateo, J., Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk (2003) Thromb. Haemost, 89, pp. 452-457
53. Legnani, C., Cini, M., Cosmi, B., Risk of deep vein thrombosis: interaction between oral contraceptives and higher factor VIII levels (2004) Haematologia, 89, pp. 1347-1351
54. Kemmeren, J.M., Algra, A., Meijers, J.C., Effect of second and third generation oral contraceptives on protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial (2004) Blood, 104, pp. 927-933
55. Heinemann, L.A., Lewis, M.A., Spitzer, W.O., Thromboembolic stroke in young women. A European case-controlled study on oral contraceptives. translational research group on oral contraceptives and the health of young women (1998) Contraception, 57, pp. 29-37
56. Wassertheil-Smoller, S., Hendrix, S.L., Limacher, M., Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial (2003) JAMA, 289, pp. 271-279
57. Cushman, M., Kuller, L.H., Prentice, R., Estrogen plus progestin and risk of venous thrombosis (2004) JAMA, 292, pp. 1573-1580
58. Smith, N.L., Heckbert, S.R., Lemaitre, R.N., Esterified estrogens and conjugated equine estrogens and risk of venous thrombosis (2004) JAMA, 292, pp. 1581-1587
59. Hulley, S., Grady, D., Bush, T., Heart and Estrogen/progestin Replacement Study (HERS). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (1998) JAMA, 280, pp. 605-612
60. Herrington, D.M., Reboussin, D.M., Effects of estrogen replacement on the progression of coronary artery atherosclerosis (2000) N Eng. J. Med, 343, pp. 522-529
61. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized Controlled Trial (2002) JAMA, 288, pp. 321-333. , Writing Group for the Women's Health Initiative Investigators
62. Glueck, C.J., Wang, P., Fontaine, R.N., Tracy, T., Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (1999) Amer. J. Cardiol, 84, pp. 549-554
63. Glueck, C.J., Wang, P., Fontaine, R.N., Sieve-Smith, L., Lang, J.E., Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women (2001) Metabolism, 50, pp. 360-365
64. Psaty, B.M., Smith, N.L., Lemaitre, R.N., Vos, H.L., Heckbert, S.R., LaCoix, A., Rosendaal, F.R., Hormone replacement therapy, prothrombotic mutations and the risk of incident non-fatal myocardial infarction in postmenopausal women (2001) JAMA, 285, pp. 906-913
65. Gardemann, A., Lohre, J., Katz, N., Tillmans, H., Hehrlein, F.W., Haberbosch, W., The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for the disease (1999) Thromb. Heamost, 82, pp. 1121-1126
66. Botto, N., Maffei, S., Manfredl, S., Colombo, M.G., Mazzone, A.M., Andreassi, M.G., Prothrombin mutations, family history, and the risk of thrombosis in postmenopausal women: Implications for hormone replacement therapy (2011) Climateric, 14, pp. 25-30
67. Dentali, F., Squizzato, A., Ageno, W., The metabolic syndrome as a risk factor for venous and arterial thrombosis (2009) Semin. Thromb. Hemost, 35, pp. 451-457
68. Subbiah, M.T.R., Cardiovascular risk associated with estrogen replacement therapy: some critical questions about the type of estrogen used in most clinical trials (2002) Atherosclerosis, 173, pp. 373-374
69. Lanas, A., Garcia-Rodriguez, L.A., Arroyo, M.T., Risk of upper gastrointestinal bleeding associated with selective COX-2 inhibitors, traditional NSAIDs, aspirin and combinations (2006) Gut, 55, pp. 1731-1738
70. Zuern, C.S., Lindemann, S., Gawaz, M., Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management (2009) Semin. Thromb. Hemost, 35, pp. 295-306
71. Erickson, H.T., Correa, M.P.F., Escobar, J.R., Guarana (1984) Econ. Botany, 38, pp. 273-286
72. Billiard, F., Martello, A., Valle, M.G., HPLC determination of caffeine and theophylline in Paullina cupana Knuth (guarana) and cola spp. samples (1985) Z. Lebanese. Enters. Forrsch, 180, pp. 398-401
73. Bempong, D., Houghton, P.J., Dissolution and absorption of caffeine from guarana (1992) J. Pharm. Pharmacol, 44, pp. 769-771
74. Bempong, D., Houghton, P.J., Steadman, K., The caffeine content of guarana (1991) J. Pharm. Pharmacol, 43 SUPPL, p. 125
75. Marx, F., Analysis of guarana seeds. II. Studies on the composition of tannin fraction (1990) J. Lebensm Unters Forsch, 190, pp. 429-431
76. Subbiah, M.T.R., Guarana consumption. A review of health benefits and risks (2005) Altern. Compliment Ther, 4, pp. 212-213
77. Haskell, C.K., Kennedy, D.O., Wesnes, K.A., Milne, A.L., Scholey, A.B., A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioral effects of guarana in humans (2007) J. Psychopharmacol, 21, pp. 65-70
78. Berube-Parent, S., Pelletier, C., Dore, J., Trembley, A., Effects of encapsulated green tea and guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 hr energy expenditure and fat oxidation in men (2005) Brit. J. Nutr, 94, pp. 432-436
79. Opala, T., Rzymski, P., Pischel, I., Wilczak, M., Wozniak, J., Efficacy of 12 weeks supplementation of a botanical extract based weight loss formula on body weight, body composition and blood chemistry in healthy overweight subjects: a randomized double-blind placebo controlled clinical trial (2006) Eur. J. Med. Res, 11, pp. 342-350
80. Bydlowski, S.P., Yunker, R.L., Subbiah, M.T.R., A novel property of aqueous guarana extracts (Paullina cupana): inhibition of platelet aggregation (1988) Bras. J. Med. Biol. Res, 21, pp. 535-538
81. Bydlowski, S.P., D'Amico, E.A., Chamone, D.A., An aqueous extract of guarana (Paullinia cupana) decreases platelet thromboxane synthesis (1991) Bras. J. Med. Biol. Res, 24, pp. 421-424
82. Subbiah, M.T.R., Yunker, R.L., Studies on the nature of anti-platelet aggregatory factors in the seeds of the Amazonian herb guarana (Paullinia cupana) (2008) Int. J. Vitam. Nutr. Res, 78, pp. 96-101
83. Oliveira, C.H., Moraes, M.E., Moraes, M.O., Bezerra, F.A., Abib, E., De Nucci, G., Clinical toxicology study of an herbal medicinal extract of Paullinia cupana, Trichilia catigua, Ptycopetalum olacoides and Zingiber officinale in healthy volunteers (2005) Phytother. Res, 19, pp. 54-57
84. Haller, C.A., Jacob, P., Benowitz, N.L., Pharmacology of ephedra alkaloids and caffeine after single dose dietary supplement use (2002) Clin. Pharmacol. Ther, 71, pp. 421-432
85. Baghkhani, L., Jafari, M., Cardiovascular adverse reactions associated with guarana: is this a causal effect? (2002) J. Herbal Pharmacology, 2, pp. 57-61
86. Gorlach, A., Redox regulation of the coagulation cascade (2005) Antioxid. Redox. Signal, 7, pp. 1398-1404
87. Essex, D.W., Redox control of platelet function (2009) Antioxid Redox Signal, 11, pp. 1191-1225
88. Coulon, L., Calzada, C., Moulin, P., Activation of p38 mitogen-activated protein hydroperoxide-stressed platelets (2003) Free Radic. Biol. Med, 35, pp. 616-625
89. Seno, T., Inooue, N., Gao, D., Involvement of NADH/NADPH oxidase in human platelet ROS production (2001) Thromb. Res, 103, pp. 399-409
90. Cieslar, P., Masova, L., Scheiner, T., Oxidative stress and platelet function in multiple myeloma and renal insufficiency: clinical relations of different states (2002) Thromb. Res, 105, pp. 277-283
91. Freeman, J.E., Keaney Jr., J.F., Vitamin E inhibition of platelet aggregation is independent of antioxidant activity (2001) J. Nutr, 131, pp. 374s-377s
92. Glynn, R.J., Ridker, P.M., Goldhaber, S.Z., Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study (2007) Circulation, 116, pp. 1497-1503
93. Loscalzo, J., Welch, G., Nitric oxide and its role in the cardiovascular system (1995) Prog. Cardiovasc. Dis, 38, pp. 87-104
94. Loscalzo, J., Nitric oxide insufficiency, platelet activation and arterial thrombosis (2001) Circ. Res, 88, pp. 756-762
95. Freedman, J.E., Frei, B., Welch, G.N., Glutathione peroxidase potentiates the inhibition of platelet function by s-nitrothiols (1995) J. Clin. Invest, 96, pp. 394-400
96. Abdulah, R., Katsuya, Y., Kobayashu, K., Effect of sodium selenite supplementation on the levels of prostacyclin I and thromboxane A2 in humans (2007) Thromb. Res, 119, pp. 305-310
97. Chakrabarthi, S., Freedman, J.E., Review: Nutriceuticals as antithrombotic agents (2010) Cardiovasc. Therapeutics, 28, pp. 227-235
98. Freedman, J.E., Parker, C., Li, L., Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release (2001) Circulation, 103, pp. 2792-2798
99. Vitseva, O., Varghese, S., Chakrabarthi, S., Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates (2005) J. Cardiovasc. Pharmacol, 46, pp. 445-451
100. Polette, A., Lemaitre, D., Lagarde, M., N-3 fatty acid-induced lipid peroxidation is prevented by catechins (1996) Thromb. Haemost, 75, pp. 945-949
101. Pignatelli, P., Lenti, L., Pulcinelli, F.M., Red and white wine differently affect collagen induced platelet aggregation (2002) Pathophysiol. Haemost. Thromb, 32, pp. 356-358
102. Pignatelli, P., Di Santo, S., Buchetti, B., Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C dependant NADPH oxidase activation: effect on platelet recruitment (2006) FASEB J, 20, pp. 1082-1089
103. Kang, W.S., Chung, K.H., Chung, J.H., Lee, J.Y., Park, J.B., Zhang, Y.H., Yoo, H.S., Yun, Y.P., Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium release (2001) J. Cardiovasc. Pharmacol, 38, pp. 875-884
104. Hodgson, J.M., Puddey, I.B., Burke, V., Beilin, L.J., Mori, T.A., Cahn, S.Y., Acute effects of ingested black tea on postprandial platelet aggregation in human subjects (2002) Brit. J. Nutr, 87, pp. 141-145
105. Kondo, K., Suzuki, Y., Ikeda, Y., Umemura, K., Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation (2002) Eur. J. Pharmacol, 455, pp. 53-57
106. McNicol, A., The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase (1993) Prostaglandins Leukot Essen Fatty Acids, 48, pp. 379-384
107. Tan, L., Kowalska, M.A., Bomo, G.M., Lopez, J.A., Darzynkiewicz, Z., Niewiarowski, S., Identification and characterization of endothelial glycoprotein 1b using viper venom proteins modulating cell adhesion Blood, 93, pp. 2605-2616
108. Casais, P., Alberto, M.F., Salviu, M.J., Pilot study of homocysteine, and cysteine in patients with thrombosis in different vascular sites (2009) Epidemiology and response to folate. Thromb. Res, 123, pp. 592-596
109. Braden, G.A., Knapp, H.R., Fitzgerlansd, D.J., Dietary fish oil accelerates the response to coronary thrombolysis with tissue-type plasminogen activator. Evidence for a modest platelet inhibitory effect in vivo (1990) Circulation, 82, pp. 178-187
110. Makheja, A.N., Bailey, J.M., Antiplatelet constituents of garlic and onion (1990) Agents Actions, 29, pp. 360-363
111. Srivastava, K.G., Tyagi, O.D., Effect of garlic derived principle (ajeone) on aggregation and arachidonic acid metabolism in human blood platelets (1993) Prostaglandins Leukot Essen Fatty Acids, 49, pp. 587-595
112. Qi, R., Liao, F., Inoue, K., Yatomi, Y., Sato, K., Ozaki, Y., Inhibition of diallyl trisulfide, a garlic component, of intracellular Ca(2+) mobilization without affecting inositol-1,4,5-triphosphate formation in activated platelets (2000) Biochem. Pharmacol, 60, pp. 1475-1483
113. Mousa, S.A., Antithrombotic effects of naturally derived products on coagulation and platelet function Anticagulants, Antiplatelets and Thrombolytics, 663, pp. 229-240. , Mousa, S. A Editor. Methods in Molecular Biology